» Articles » PMID: 35464420

Genetic Modifiers of Thymic Selection and Central Tolerance in Type 1 Diabetes

Overview
Journal Front Immunol
Date 2022 Apr 25
PMID 35464420
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 diabetes (T1D) is caused by the T cell-driven autoimmune destruction of insulin-producing cells in the pancreas. T1D served as the prototypical autoimmune disease for genome wide association studies (GWAS) after having already been the subject of many linkage and association studies prior to the development of GWAS technology. Of the many T1D-associated gene variants, a minority appear disease-specific, while most are shared with one or more other autoimmune condition. Shared disease variants suggest defects in fundamental aspects of immune tolerance. The first layer of protective tolerance induction is known as central tolerance and takes place during the thymic selection of T cells. In this article, we will review candidate genes for type 1 diabetes whose function implicates them in central tolerance. We will describe examples of gene variants that modify the function of T cells intrinsically and others that indirectly affect thymic selection. Overall, these insights will show that a significant component of the genetic risk for T1D - and autoimmunity in general - pertains to the earliest stages of tolerance induction, at a time when protective intervention may not be feasible.

Citing Articles

Type 1 diabetes: immune pathology and novel therapeutic approaches.

Ling E, Lemos J, Hirani K, von Herrath M Diabetol Int. 2024; 15(4):761-776.

PMID: 39469552 PMC: 11512973. DOI: 10.1007/s13340-024-00748-z.


Rational Engineering of Islet Tolerance via Biomaterial-Mediated Immune Modulation.

Klug N, Burke J, Scott E J Immunol. 2024; 212(2):216-224.

PMID: 38166244 PMC: 10766078. DOI: 10.4049/jimmunol.2300527.


The countdown to type 1 diabetes: when, how and why does the clock start?.

Ziegler A Diabetologia. 2023; 66(7):1169-1178.

PMID: 37231274 PMC: 10212739. DOI: 10.1007/s00125-023-05927-2.

References
1.
Schloss J, Ali R, Racine J, Chapman H, Serreze D, DiLorenzo T . HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression. J Immunol. 2018; 200(10):3353-3363. PMC: 5940557. DOI: 10.4049/jimmunol.1701652. View

2.
Doody K, Bourdeau A, Tremblay M . T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunol Rev. 2009; 228(1):325-41. DOI: 10.1111/j.1600-065X.2008.00743.x. View

3.
Bradfield J, Qu H, Wang K, Zhang H, Sleiman P, Kim C . A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. PLoS Genet. 2011; 7(9):e1002293. PMC: 3183083. DOI: 10.1371/journal.pgen.1002293. View

4.
Dikiy S, Li J, Bai L, Jiang M, Janke L, Zong X . A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity. 2021; 54(5):931-946.e11. PMC: 8317508. DOI: 10.1016/j.immuni.2021.03.020. View

5.
Nistico L, Buzzetti R, Pritchard L, Van der Auwera B, Giovannini C, Bosi E . The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet. 1996; 5(7):1075-80. DOI: 10.1093/hmg/5.7.1075. View